NF-κB: An essential transcription factor in psoriasis

Journal of Dermatological Science

Volumn 69, Issue 2, 2013, Pages 89-94

  Goldminz, A M ^a   Au, S C ^a   Kim, N ^a   Gottlieb, A B ^a   Lizzul, P F ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Inflammation; Keratinocytes; NF B; Psoriasis; T cells; TNF

Indexed keywords

BORTEZOMIB; CALCIPOTRIOL; DITHRANOL; ETANERCEPT; GLUCOCORTICOID; I KAPPA B ALPHA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; PLACEBO; PROTEIN A20; PROTEIN P53; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

CARD14 GENE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DIMERIZATION; DISEASE ASSOCIATION; DRUG MECHANISM; GENE; HISTORY OF MEDICINE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INTRACELLULAR SIGNALING; KERATINOCYTE; MISSENSE MUTATION; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHOTOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PSORIASIS; REGULATORY MECHANISM; REVIEW; TH17 CELL;

HUMANS; NF-KAPPA B P50 SUBUNIT; NF-KAPPA B P52 SUBUNIT; PSORIASIS; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC;

EID: 84873567016     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2012.11.002     Document Type: Review

References (50)

1. Baltimore D. Discovering NF-kappaB. Cold Spring Harb Perspect Biol 2009, 1:a000026.
2. Hozumi N., Tonegawa S. Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. Proc Natl Acad Sci USA 1976, 73:3628-3632.
3. Sen R. The origins of NF-kappaB. Nat Immunol 2011, 12:686-688.
4. Lawrence T., Gilroy D.W., Colville-Nash P.R., Willoughby D.A. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 2001, 7:1291-1297.
5. Perkins N.D., Schmid R.M., Duckett C.S., Leung K., Rice N.R., Nabel G.J. Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation. Proc Natl Acad Sci USA 1992, 89:1529-1533.
6. Jacobs M.D., Harrison S.C. Structure of an IkappaBalpha/NF-kappaB complex. Cell 1998, 95:749-758.
7. Ghosh S., Baltimore D. Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature 1990, 344:678-682.
8. Claudio E., Brown K., Park S., Wang H., Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 2002, 3:958-965.
9. Dejardin E., Droin N.M., Delhase M., Haas E., Cao Y., Makris C., et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002, 17:525-535.
10. Lizzul P.F., Aphale A., Malaviya R., Sun Y., Masud S., Dombrovskiy, et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 2005, 124:1275-1283.
11. Tsuruta D. NF-kappaB links keratinocytes and lymphocytes in the pathogenesis of psoriasis. Recent Pat Inflamm Allergy Drug Discov 2009, 3:40-48.
12. Begon E., Michel L., Flageul B., Beaudoin I., Jean-Louis F., Bachelez H., et al. Expression, subcellular localization and cytokinic modulation of Toll-like receptors (TLRs) in normal human keratinocytes: TLR2 up-regulation in psoriatic skin. Eur J Dermatol 2007, 17:497-506.
13. Salskov-Iversen M.L., Johansen C., Kragballe K., Iversen L. Caspase-5 expression is upregulated in lesional psoriatic skin. J Invest Dermatol 2011, 131:670-676.
14. Weinstein G.D., McCullough J.L., Ross P.A. Cell kinetic basis for pathophysiology of psoriasis. J Invest Dermatol 1985, 85:579-583.
15. Gosh S., Hayden M.S. Celebrating 25 years of NF-κB research. Immunol Rev 2012, 246:5-13.
16. Abdou A.G., Hanout H.M. Evaluation of survivin and NF-kappaB in psoriasis, an immunohistochemical study. J Cutan Pathol 2008, 35:445-451.
17. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362.
18. Johansen C., Riis J.L., Gedebjerg A., Kragballe K., Iversen L. Tumor necrosis factor alpha-mediated induction of interleukin 17C in human keratinocytes is controlled by nuclear factor kappaB. J Biol Chem 2011, 286:25487-25494.
19. Kagami S., Rizzo H.L., Lee J.J., Koguchi Y., Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2009, 130:1373-1383.
20. Liu Y., Lagowski J.P., Gao S., Raymond J.H., White C.R., Kulesz-Martin M.F. Regulation of the psoriatic chemokine CCL20 by E3 ligases Trim32 and Piasy in keratinocytes. J Invest Dermatol 2010, 130:1384-1390.
21. Vestergaard C., Johansen C., Otkjaer K., Deleuran M., Iversen L. Tumor necrosis factor-α-induced CTACK/CCL27 (cutaneous T-cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor κB. Cytokine 2005, 29:49-55.
22. Rebholz B., Haase I., Eckelt B., Paxian S., Flaig M.J., Ghoreschi K., et al. Crosstalk between keratinocytes and adaptive immune cells in an IkappaBalpha protein-mediated inflammatory disease of the skin. Immunity 2007, 27:296-307.
23. Elder J.T. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun 2009, 10:201-209.
24. Nair R.P., Duffin K.C., Helms C., Ding J., Stuart P.E., Goldgar D., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009, 41:199-204.
25. Sun L.D., Cheng H., Wang Z.X., Zhang A.P., Wang P.G., Xu J.H., et al. Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet 2010, 42:1005-1009.
26. Stuart P.E., Nair R.P., Ellinghaus E., Ding J., Tejasvi T., Gudjonsson J.E., et al. Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet 2010, 42:1000-1004.
27. Hüffmeier U., Uebe S., Ekici A.B., Bowes J., Giardina E., Korendowych E., et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet 2010, 42:996-999.
28. Idel S., Dansky H.M., Breslow J.L. A20, a regulator of NFkappaB, maps to an atherosclerosis locus and differs between parental sensitive C57BL/6J and resistant FVB/N strains. Proc Natl Acad Sci USA 2003, 100:14235-14240.
29. Wu L., Zepp J., Li X. Function of Act1 on IL-17 family signaling and autoimmunity. Adv Exp Med Biol 2012, 946-1035.
30. Jordan C.T., Cao L., Roberson E.D.O., Duan S., Helms C.A., Nair R.P., et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet 2012, 90:1-13.
31. Heenen M., Simonart T. Biological agents and psoriatic epidermis: what are we ultimately targeting?. Dermatology 2006, 212:321-323.
32. Avramidis G., Kruger-Krasagakis S., Krasagakis K., Fragiadaki I., Kokolakis G., Tosca A. The role of endothelial cell apoptosis in the effect of etanercept in psoriasis. Br J Dermatol 2010, 163:928-934.
33. Scheinman R.I., Cogswell P.C., Lofquist A.K., Baldwin A.S. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995, 270:283-286.
34. Scheinman R.I., Gualberto A., Jewell C.M., Cidlowski J.A., Baldwin A.S. Characterization of mechanisms involved in transrepression of NF-B by activated glucocorticoid receptors. Mol Cell Biol 1995, 15:943-953.
35. Schmidt K.N., Podda M., Packer L., Baeuerle P.A. Anti-psoriatic drug anthralin activates transcription factor NF-kappa B in murine keratinocytes. J Immunol 1996, 156:4514-4519.
36. Simon M.M., Aragane Y., Schwarz A., Luger T.A., Schwarz T. UVB light induces nuclear factor kappa B (NF kappa B) activity independently from chromosomal DNA damage in cell-free cytosolic extracts. J Invest Dermatol 1994, 102:422-427.
37. Johansen C., Flindt E., Kragballe K., Henningsen J., Westergaard M., Kristiansen K., et al. Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin. J Invest Dermatol 2005, 124:1284-1292.
38. Farkas á., Kemény L., Szóny B.J., Bata-Csörgó Z., Pivarcsi A., Kiss M., et al. Dithranol upregulates IL-10 receptors on the cultured human keratinocyte cell line HaCaT. Inflamm Res 2001, 50:44-49.
39. Enk C.D., Sredni D., Blauvelt A., Katz S.I. Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro. J Immunol 1995, 154:4851-4856.
40. Gilmore T.D., Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 2006, 25:6887-6899.
41. Wong E.T., Tergaonkar V. Roles of NF-kappaB in health and disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2009, 116:451-465.
42. Gillooly K.M., Pattoli M.A., Taylor T.L., Chen L., Cheng L., Gregor K.R., et al. Periodic, partial inhibition of IkappaB kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis. J Pharmacol Exp Ther 2009, 331:349-360.
43. Wang H., Syrovets T., Kess D., Büchele B., Hainzl H., Lunov O., et al. Targeting NF-kappa B with a natural triterpenoid alleviates skin inflammation in a mouse model of psoriasis. J Immunol 2009, 183:4755-4763.
44. Kielar D., Kaminski W.E., Liebisch G., Piehler A., Wenzel J.J., Möhle C., et al. Adenosine triphosphate binding cassette (ABC) transporters are expressed and regulated during terminal keratinocyte differentiation: a potential role for ABCA7 in epidermal lipid reorganization. J Invest Dermatol 2003, 121:465-474.
45. Gareus R., Huth M., Breiden B., Nenci A., Rösch N., Haase I., et al. Normal epidermal differentiation but impaired skin-barrier formation upon keratinocyte-restricted IKK1 ablation. Nat Cell Biol 2007, 9:461-469.
46. Potapovich A.I., Lulli D., Fidanza P., Kostyuk V.A., De Luca C., Pastore S., et al. Plant polyphenols differentially modulate inflammatory responses of human keratinocytes by interfering with activation of transcription factors NFkappaB and AhR and EGFR-ERK pathway. Toxicol Appl Pharmacol 2011, 255:138-149.
47. Saelee C., Thongrakard V., Tencomnao T. Effects of Thai medicinal herb extracts with anti-psoriatic activity on the expression on NF-kappaB signaling biomarkers in HaCaT keratinocytes. Molecules 2011, 16:3908-3932.
48. Wang H., Peters T., Kess D., Sindrilaru A., Oreshkova T., Van Rooijen N., et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 2006, 116:2105-2114.
49. Zollner T.M., Podda M., Pien C., Elliott P.J., Kaufmann R., Boehncke W.H. Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest 2002, 109:671-677.
50. Tung D., Cheung P.H., Kaur P., Foreman O., Kavirayani A., Hain H.S., et al. Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models. Pharmacology 2011, 88:100-113.